Johnson & Johnson (NYSE:JNJ ) BofA Securities Health Care Conference Transcript May 14, 2024 4:40 PM ET Executives John Reed - Executive Vice President, Innovative Medicine, R&D Analysts Geoff Meacham - Bank of America Charlie Yang - Bank of America Geoff Meacham The afternoon sessions of the first day of the BofA Healthcare Conference. My name is Geoff Meacham, I'm the Senior Biopharma Analyst...
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck (NYSE: MRK). Although Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2x for J&J, we think that this valuation gap will likely narrow over the coming years in favor of J&J, given its superior profitability and better prospects.
Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dulled the appetite on Wall Street for deal-making.
Kenvue (NYSE: KVUE ) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE: JNJ ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock.
Dividend stocks from some of your favorite businesses can help boost your returns. J&J is benefitting from a vast portfolio of medicines and a resurgence in surgical procedures.
Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.
One of the most important things stock investors should look at is the fundamentals of a company. Each earnings season shows us how a compare fares and we get this idea through the fundamentals.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.